The Ohio State University AIDS Clinical Trials Unit

俄亥俄州立大学艾滋病临床试验中心

• 批准号: 7340528
• 负责人: SUSAN L KOLETAR
• 金额: $ 254.21万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-01-18 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7340528
• 关键词: AIDS clinical trial group; Acquired Immunodeficiency Syndrome; Address; Adverse effects; Age; Agreement; Area; Behavior Therapy; California; Caring; Child; Clinical Management; Clinical Research; Clinical Trials; Clinical Trials Design; Communities; Disease Progression; Economic Conditions; Elements; Enrollment; HIV; HIV Infections; HIV vaccine; Hepatitis; Human Resources; Individual; Interruption; Knowledge; Laboratories; Nurses; Ohio; Pathogenesis; Pharmacy facility; Prevention; Prevention strategy; Productivity; Protocols documentation; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Research Priority; Risk; Safety; Scientist; Techniques; Testing; Toxic effect; Tuberculosis; Universities; Vaccine Adjuvant; Vaccines; Vertical Disease Transmission; Washington; Woman; data management; design; experience; immunogenicity; improved; novel; outreach; prevent; transmission process; vaccine evaluation

DESCRIPTION (provided by applicant): The Ohio State University (OSU) AIDS Clinical Trials Unit (ACTU) plans to conduct clinical research that will increase knowledge about the pathogenesis, prevention, course, and treatment of HIV infection and its associated complications through affiliation by prior agreement with the AIDS Clinical Trials Group (ACTG) led by Dr. Constance Benson of the University of California, San Diego, CA and also proposes to affiliate with the HIV Vaccine Trials Network (HVTN) led by Dr. Lawrence Corey of the University of Washington, Seattle WA. Clinical trials will be designed and implemented: 1) to optimize the clinical management of HIV and its related complications; 2) to evaluate agents with novel mechanisms of action or improved toxicity profiles for the treatment of HIV and/or for major copathogens (such as tuberculosis and hepatitis); 3) to evaluate the safety, immunogenicity, and efficacy of multiple candidate HIV vaccines and adjuvants; 4) to develop means of reducing HIV transmission by integrating HIV treatment with prevention efforts that evaluate practical behavioral interventions and other methods of transmission interruption; and 5) to minimize the risk of vertical transmission by maximizing care of HIV-infected women during their child-bearing years. HIV-infected individuals from a wide spectrum of ages, communities and socio-economic conditions will be recruited, screened and enrolled in specific protocols that address these high priority research areas at the OSU ACTU. Coordination of research related activities and timely execution of new studies will take advantage of established investigator expertise, ongoing productive partnerships with scientist colleagues and the HIV-infected community and a clinical research infrastructure that is recognized for its productivity in the ACTG over the past 18 years and more recently in large scale vaccine and prevention trials. Experienced research staff (investigators, nurses, pharmacy, data management, laboratory and outreach personnel) will recruit, screen, enroll and rummage all essential and required elements of clinical trials participation. Clinical research that develops and tests strategies and new treatments for HIV infection and its complications is critically important for controlling HIV disease progression and minimizing side effects. Well-designed clinical trials to test vaccines and other preventive strategies are essential to preventing the spread of HIV infection. ADMINISTRATIVE COMPONENT:

描述（申请人提供）：俄亥俄州州立大学（OSU）艾滋病临床试验单位（ACTU）计划进行临床研究，通过事先与艾滋病临床试验组（ACTG）达成协议，增加对艾滋病毒感染及其相关并发症的发病机制、预防、病程和治疗的了解，该临床试验组由位于圣地亚哥的加州大学的康斯坦斯·本森博士领导。CA还提议与由华盛顿州西雅图华盛顿大学的劳伦斯·科里博士领导的艾滋病毒疫苗试验网络（HVTN）建立联系。将设计和实施临床试验：1）优化艾滋病毒及其相关并发症的临床管理; 2）评估具有新作用机制或改善毒性特征的药物用于治疗艾滋病毒和/或主要病原体（如结核病和肝炎）; 3）评估多种候选HIV疫苗和佐剂的安全性、免疫原性和有效性;（4）通过将艾滋病毒治疗与评估实际行为干预和其他阻断传播方法的预防工作相结合，制定减少艾滋病毒传播的手段;（5）通过最大限度地照顾育龄期感染艾滋病毒的妇女，尽量减少垂直传播的风险。来自不同年龄、社区和社会经济条件的艾滋病毒感染者将被招募、筛选和登记参加OSU ACTU针对这些高度优先研究领域的具体方案。研究相关活动的协调和新研究的及时执行将利用已建立的研究者专业知识，与科学家同事和艾滋病毒感染社区的持续有效伙伴关系，以及在过去18年中在ACTG中以及最近在大规模疫苗和预防试验中因其生产力而获得认可的临床研究基础设施。经验丰富的研究人员（研究者、护士、药房、数据管理、实验室和外展人员）将招募、筛选、入组和搜索参与临床试验的所有基本和必需要素。开发和测试艾滋病毒感染及其并发症的策略和新疗法的临床研究对于控制艾滋病毒疾病进展和最大限度地减少副作用至关重要。设计良好的临床试验来测试疫苗和其他预防战略对于预防艾滋病毒感染的传播至关重要。 行政部门：